NEW YORK (GenomeWeb News) – Plant genomics firm Evogene has gone public in the US through the offering of 5 million shares of common stock at an offering price of $14.75 per share, bringing in gross proceeds of $73.75 million.
The firm has granted the underwriters a 30-day option to purchase up to 750,000 additional ordinary shares at the same offering price per share.
The Israel-based company, which also trades on the Tel Aviv Stock Exchange, filed to go public in the US in September, saying at the time that it intended to offer $60 million of its shares.
Evogene said that agricultural products giant Monsanto has agreed to purchase 813,560 ordinary shares as part of the offering for approximately US$12 million.
Evogene's shares are expected to begin trading today on the New York Stock Exchange under the symbol "EVGN."
Credit Suisse Securities and Deutsche Bank Securities acted as joint book-running managers on the planned offering, while Oppenheimer and Piper Jaffray were co-managers.